Delayed
Canadian Securities Exchange
01:05:12 2021-10-04 pm EDT
|
5-day change
|
1st Jan Change
|
0.02
CAD
|
-20.00%
|
|
+25.00%
|
+66.67%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
60.82
|
32.02
|
5.851
|
6.473
|
3.668
|
3.681
|
Enterprise Value (EV)
1 |
64.74
|
27.7
|
6.154
|
2.376
|
3.396
|
5.078
|
P/E ratio
|
-2.03
x
|
-1.43
x
|
-0.84
x
|
-2.53
x
|
-0.54
x
|
-1.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
22.6
x
|
43
x
|
291
x
|
9.46
x
|
11.5
x
|
0.78
x
|
EV / Revenue
|
24.1
x
|
37.2
x
|
306
x
|
3.47
x
|
10.7
x
|
1.07
x
|
EV / EBITDA
|
-3.16
x
|
-2.72
x
|
-1.87
x
|
-0.76
x
|
-1.27
x
|
-3.6
x
|
EV / FCF
|
-5.08
x
|
-11.4
x
|
-2.51
x
|
-1.59
x
|
-5.28
x
|
-15.2
x
|
FCF Yield
|
-19.7%
|
-8.8%
|
-39.9%
|
-63%
|
-18.9%
|
-6.56%
|
Price to Book
|
1.7
x
|
2.43
x
|
0.69
x
|
1
x
|
0.58
x
|
0.87
x
|
Nbr of stocks (in thousands)
|
32,009
|
32,015
|
39,008
|
43,154
|
73,355
|
73,628
|
Reference price
2 |
1.900
|
1.000
|
0.1500
|
0.1500
|
0.0500
|
0.0500
|
Announcement Date
|
5/11/20
|
5/11/20
|
4/21/21
|
4/12/22
|
4/28/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2.688
|
0.744
|
0.0201
|
0.6842
|
0.3188
|
4.744
|
EBITDA
1 |
-20.46
|
-10.18
|
-3.284
|
-3.118
|
-2.673
|
-1.41
|
EBIT
1 |
-23.36
|
-10.97
|
-4.098
|
-3.682
|
-2.9
|
-1.685
|
Operating Margin
|
-868.9%
|
-1,475.03%
|
-20,406.36%
|
-538.14%
|
-909.79%
|
-35.52%
|
Earnings before Tax (EBT)
1 |
-30.49
|
-22.39
|
-6.435
|
-2.381
|
-4.578
|
-2.071
|
Net income
1 |
-29.77
|
-22.4
|
-6.438
|
-2.396
|
-4.615
|
-2.071
|
Net margin
|
-1,107.63%
|
-3,010.1%
|
-32,061.99%
|
-350.13%
|
-1,447.78%
|
-43.66%
|
EPS
2 |
-0.9368
|
-0.6996
|
-0.1780
|
-0.0593
|
-0.0923
|
-0.0295
|
Free Cash Flow
1 |
-12.75
|
-2.438
|
-2.454
|
-1.498
|
-0.6429
|
-0.3333
|
FCF margin
|
-474.47%
|
-327.73%
|
-12,219.52%
|
-218.98%
|
-201.7%
|
-7.03%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/11/20
|
5/11/20
|
4/21/21
|
4/12/22
|
4/28/23
|
4/30/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
3.93
|
-
|
0.3
|
-
|
-
|
1.4
|
Net Cash position
1 |
-
|
4.32
|
-
|
4.1
|
0.27
|
-
|
Leverage (Debt/EBITDA)
|
-0.1919
x
|
-
|
-0.0922
x
|
-
|
-
|
-0.9905
x
|
Free Cash Flow
1 |
-12.8
|
-2.44
|
-2.45
|
-1.5
|
-0.64
|
-0.33
|
ROE (net income / shareholders' equity)
|
-83.8%
|
-91.6%
|
-59.5%
|
-32.1%
|
-72.3%
|
-39.4%
|
ROA (Net income/ Total Assets)
|
-29.7%
|
-22.5%
|
-20.3%
|
-24.5%
|
-23.9%
|
-13.1%
|
Assets
1 |
100.2
|
99.44
|
31.69
|
9.786
|
19.34
|
15.86
|
Book Value Per Share
2 |
1.120
|
0.4100
|
0.2200
|
0.1500
|
0.0900
|
0.0600
|
Cash Flow per Share
2 |
0.0400
|
0.1200
|
0.0500
|
0.0900
|
0.0200
|
0
|
Capex
1 |
21.6
|
-
|
0.09
|
0.08
|
0.03
|
0.01
|
Capex / Sales
|
802.08%
|
-
|
430.8%
|
12.07%
|
10.42%
|
0.13%
|
Announcement Date
|
5/11/20
|
5/11/20
|
4/21/21
|
4/12/22
|
4/28/23
|
4/30/24
|
|
1st Jan change
|
Capi.
|
---|
| +12.92% | 4.95B | | -32.29% | 3.6B | | -4.28% | 3.03B | | -24.21% | 2.66B | | -8.82% | 2.34B | | +39.33% | 1.85B | | +40.81% | 1.45B | | -14.27% | 1.41B | | +41.90% | 1.38B |
Alternative Medicine
|